The recently-published consensus statement for heart failure management cements the place of SGLT2 inhibitors as ‘cornerstone therapy’ in HFrEF and broadens the scope of ARNI use in HFrEF and HFmrEF. The guidance was developed by a working group led by Prof. Andrew Sindone, A/Prof. Carmine De Pasquale and Prof. John Atherton.
In this podcast, Prof. Sindone talks through the key recommendations for practicing clinicians and provides some context around the reasons for the updated guidance.
This podcast was sponsored by Astra Zeneca. Any views expressed are those of the experts alone and do not necessarily reflect the views of the sponsor. Before prescribing, please review all relevant product information via the TGA website. Treatment decisions based on information in this podcast are the responsibility of the prescribing physician.